Point72 Asset Management
HRTX icon

Point72 Asset Management’s Heron Therapeutics HRTX Stock Holding History

Point72 Asset Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,000,000
Closed -$2.5M – 2376
2022
Q4 		$2.5M Buy
+1,000,000
New +$3.22M 0.01% 896

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Point72 Asset Management's HRTX Position: Q2 2025 in Review

Point72 Asset Management sold out of Heron Therapeutics (HRTX) in Q2 2025, closing a stake of 4,775,877 shares — an estimated $10.5M sold.

Point72 Asset Management first reported a position in HRTX in Q4 2014 and held it in 17 quarters. The position peaked at $17.1M in Q3 2021. 171 funds tracked by Wall St. Rank hold HRTX as of Q2 2025.

  • Point72 Asset Management reported no remaining Heron Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Point72 Asset Management sold 4,775,877 Heron Therapeutics shares in Q2 2025, an estimated $10.5M.
  • Point72 Asset Management first reported a position in Heron Therapeutics in Q4 2014 and held it in 17 quarters.
  • Point72 Asset Management's Heron Therapeutics position peaked at $17.1M in Q3 2021.
  • 171 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2025.

Based on Point72 Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.